HolmesAI (CEO Dong Seok Lim) participated in the AVING Space Studio interview at CES 2025 on January 8 (local time).
AVING News, celebrating its 20th anniversary of covering CES, operated a studio during the exhibition to feature global companies and innovative Korean startups, conducting live interviews throughout the event.
HolmesAI, a spin-off from SCL Healthcare Group in 2023, specializes in medical AI solutions designed to support diagnostics, treatment, and health management. Their flagship platform, CLholmes®, employs AI to diagnose and predict heart diseases, the leading cause of death globally, while also addressing conditions such as sleep apnea and respiratory illnesses.
HolmesAI aims to enhance health outcomes through AIoMT (Artificial Intelligence, Internet of Medical Things), combining AI with medical IoT technology. Their AI-powered electrocardiogram (ECG) analysis and prediction technologies have been published in leading international journals such as the NIH National Library of Medicine and other reputable computer and biomedical journals.
The CLholmes® platform was recognized as a CES 2025 Innovation Award Honoree in the ‘Accessibility & AgeTech’ category for its contribution to improving senior health management. The platform uses AI to detect and predict heart diseases common in older adults, offering early warning and prevention capabilities.
CLholmes® employs patented AI technology to diagnose 21 types of arrhythmias with high accuracy and predict potential risks up to six months in advance, significantly outperforming existing solutions. It integrates ultra-compact wearable patches and digital therapeutics for real-time health monitoring and preventative care, providing immense value for senior populations.
The wearable ECG patch is designed for ease of use. It is lightweight and unobtrusive during daily activities. Its application on the chest enables continuous monitoring without inconvenience.
HolmesAI’s CLholmes® is connected to the SCL Group’s cardiac data center, enhancing diagnostic accuracy for healthcare professionals. The technology offers advanced diagnostic services globally through a cloud-based AI platform, including in developing countries with limited access to specialized cardiologists. This aligns with CES’s focus on “human security.”
Kwang Hyun Lee, CSO of HolmesAI’s Future Growth Division, stated, “We will continue to upgrade core technologies like AI, IoMT, and digital therapeutics to help seniors manage health risks in everyday life.”
HolmesAI plans to establish a U.S. office in Boston by 2025 and secure FDA approval. Leveraging SCL Group’s global healthcare network, the company aims to expand its reach to the U.S., Indonesia, the UAE, and beyond.
HolmesAI’s parent company, SCL Group, founded in 1983, is a comprehensive healthcare organization. It includes entities such as SCL, Korea’s first specialized testing agency; SCL Healthcare, a global clinical trial specimen analysis institution; Hanaro Medical Foundation, a leading health screening center; and SCL Holdings. The group establishes global diagnostic healthcare systems through overseas subsidiaries in Mongolia, Indonesia, and more.
AVING News, which has covered CES for 19 consecutive years, continues to bridge the gap for Korean SMEs and startups looking to expand globally. To promote Korean startups worldwide, AVING will host its Broadcasting Zone at the Venetian Expo, featuring the CES Media Day Startup Conference and global media interviews. AVING’s international media partners will cover these programs.
Following CES 2025, AVING will co-host review conferences with participating companies in Korea, offering a platform for increased visibility and improved corporate image.
Special Coverage Team: Joseph Choe, Kidai Kim, Dongkwan Kim, Mokkyung Lee, Sangun Choi, Seung Hyun Nam, Min Choi, Minseok Cha, Myungjin Shin, Gyeongha Lee, Jaeman Lee.
